News

Caldic announces partnership with BIO-CAT to bring innovative probiotics to the Companion Animal Health and Nutrition industry

BIO-CAT, Inc., an industry leading probiotic manufacturer, has agreed to partner with global distribution solutions provider Caldic North America to bring their proprietary probiotic strains and OPTIFEED® branded solutions to the Companion Animal Health and Nutrition market in North America. This agreement secures a rapid go-to-market strategy for BIO-CAT, leveraging Caldic’s leadership position in the Companion Animal market as a provider of value-add antioxidant, vitamin, mineral, and ingredient solutions.

Founded in Keswick, Virginia, BIO-CAT is an industry-leading expert in specialty enzyme and probiotic formulations. The company offers an extensive range of single-to-multi-enzyme blends and unique microbial solutions for better animal digestive health. BIO-CAT Microbials, located in Shakopee Minnesota, is BIO-CAT’s vertically integrated FDA registered and SQF certified (human-grade) U.S. fermentation facility. Their AAFCO-listed OPTIFEED® probiotic strains are premium, safe, effective, and have shown physiological benefits to companion animals in support of their gastrointestinal and digestive health; similar to the benefits they deliver to humans. Future expansion of the OPTIFEED® line of enzymes will further support digestive health, enhancing the nutritional value of pet food, and can be used in ingredient processing and flavor development.

“This partnership with BIO-CAT significantly strengthens Caldic’s existing Companion Animal portfolio,” says Liz Parker, Director of Companion Animal Health & Nutrition, Caldic North America, “adding a range of innovative and customizable solutions to inspire quality pet food and health. As the importance of pet companionship is widely recognized, domestic animal owners are increasingly keen to provide their pets with nutritionally high-performing food, treats and supplements. The expert know-how our R&D team has acquired in pet food when formulating with our antioxidants range, Dadex®, and our custom vitamin and mineral blends, Daminaide®, will greatly benefit the solutions we can deliver across North America while partnering with BIO-CAT.”

“BIO-CAT Microbials’ expertise in probiotic strain development and fermentation is a great match for Caldic’s exceptional distribution solutions,” says Chris Schuler, President and CEO of BIO-CAT. “We value Caldic’s commitment to the Companion Animal space and their ability to scale our OPTIFEED® probiotic business within their customer base. We look forward to a successful collaboration and exclusive partnership with Caldic.”

Recent News

02/20/2025

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

“Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return

02/11/2025

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions,  announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI). This collaboration seeks to develop the first intranasal therapy for mild traumatic brain injury (mTBI) aka concussion, creating a comprehensive trigger-to-treat

02/11/2025

Children’s National and Compremium partner on pediatric medtech innovation

Children’s National Hospital announced a new collaboration with Swiss medical device company Compremium AG to co-develop and commercialize innovative medical technologies designed specifically for pediatric patients. This first-of-its-kind agreement leverages the expertise of Children’s National in pediatric healthcare innovation and Compremium’s non-invasive platform technology for diagnosing pressure-related conditions, accelerating advancements in pediatric medicine. Diagnosing pressure-related